Genmab A/S (GMAB) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the GENMAB first half 2025 financial results conference call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. GENMAB is not under any obligation to update statements regarding the future nor to confirm such statements in relation to the actual results unless this is required by law. Please note that GENNAB may hold your personal data as indicated by you as part of our investor relations outreach activities in order to update you on GENNAB going forward. Please refer to our website for more information on GenMap and our privacy policy. I would now like to turn the conference over to your first speaker today, Jan van de Winkel. Please go ahead. Hello, and welcome to our financial results for the first half of 2025. With me today is our Chief Financial Officer, Anthony Pagano, our Chief Commercial Officer, Brad Bailey, and our Chief Medical Officer, Tai Yamadi. And for the Q&A, we will be joined by our Chief Development Officer, Judith Klimowski. As we have already said, we will be making forward-looking statements, so please keep that in mind during the call. During today's presentation, we will reference products being developed under some of our strategic collaborations. This slide acknowledges those relationships. I would like to start with a reminder of our commitments for 2025. In February, we said that we would accelerate the development of our high impact late stage pipeline, that we would maximize the potential of our commercialized medicines, and that we would deliver on...